Revenue, Credit Concentrations and Geographic Information - Disaggregates of Net Product Revenues by Product (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue from External Customer [Line Items]
Revenue	$ 519,359	$ 486,030
Product
Revenue from External Customer [Line Items]
Revenue	505,525	467,769
Vimizim | Marketed by Company
Revenue from External Customer [Line Items]
Revenue	183,059	158,298
Naglazyme | Marketed by Company
Revenue from External Customer [Line Items]
Revenue	128,031	107,336
Kuvan | Marketed by Company
Revenue from External Customer [Line Items]
Revenue	59,337	70,763
Palynziq | Marketed by Company
Revenue from External Customer [Line Items]
Revenue	54,885	54,038
Brineura | Marketed by Company
Revenue from External Customer [Line Items]
Revenue	36,173	27,325
Voxzogo | Marketed by Company
Revenue from External Customer [Line Items]
Revenue	19,658	0
Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim | Marketed by Company
Revenue from External Customer [Line Items]
Revenue	481,143	417,760
Aldurazyme | Marketed by Sanofi
Revenue from External Customer [Line Items]
Revenue	24,382	50,009
Royalty and other revenues
Revenue from External Customer [Line Items]
Revenue	$ 13,834	$ 18,261